225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

A remarkable therapeutic efficacy has been demonstrated with Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metast...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of nuclear medicine and molecular imaging Vol. 46; no. 1; p. 129
Main Authors:	Sathekge, Mike, Bruchertseifer, Frank, Knoesen, Otto, Reyneke, Florette, Lawal, Ismaheel, Lengana, Thabo, Davis, Cindy, Mahapane, Johncy, Corbett, Ceceila, Vorster, Mariza, Morgenstern, Alfred
Format:	Journal Article
Language:	English
Published:	Germany 01-01-2019
Subjects:	Actinium - adverse effects Actinium - therapeutic use Aged Aged, 80 and over Carcinoma - diagnostic imaging Carcinoma - pathology Carcinoma - radiotherapy Dipeptides - adverse effects Dipeptides - therapeutic use Edetic Acid - analogs & derivatives Heterocyclic Compounds, 1-Ring - adverse effects Heterocyclic Compounds, 1-Ring - therapeutic use Humans Male Middle Aged Oligopeptides Pilot Projects Positron Emission Tomography Computed Tomography Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radiopharmaceuticals - adverse effects Radiopharmaceuticals - therapeutic use Actinium-225 PSMA PSA response Radioligand therapy Chemotherapy-naïve Prostate cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!